Research Topics
| Jacob LaubachSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms MacroglobulinemiaJacob P Laubach
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
Leuk Lymphoma 50:694-702. 2009....- The use of novel agents in the treatment of relapsed and refractory multiple myelomaJ P Laubach
Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA, USA
Leukemia 23:2222-32. 2009..This review focuses on the role of thalidomide, lenalidomide and bortezomib in relapsed and refractory MM, with additional discussion dedicated to emerging drugs in relapsed MM that may prove beneficial to patients with this disease... 
Novel therapies in the treatment of multiple myelomaJacob P Laubach
Harvard Medical School and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
J Natl Compr Canc Netw 7:947-60. 2009..In aggregate, the use of novel therapies in MM has been associated with substantial improvements in patient outcome...
The evolution and impact of therapy in multiple myelomaJacob P Laubach
Department of Medical Oncology, Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA, USA
Med Oncol 27:S1-6. 2010..As a result of these developments, clinical outcomes have improved significantly. This review highlights important historic landmarks as well as more recent events that have played an important role in the evolution of myeloma therapy...- Management of relapsed and relapsed/refractory multiple myelomaJacob P Laubach
Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
J Natl Compr Canc Netw 9:1209-16. 2011..Moreover, the development of new drug classes based on preclinical rationale and the introduction of next-generation agents is likely to further expand treatment options and improve outcomes for relapsed MM... - Multiple myelomaJacob Laubach
Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Annu Rev Med 62:249-64. 2011..This review highlights important historical landmarks in the field of MM, examines the pathogenesis and clinical manifestations of the disease, and outlines principles of both diagnosis and treatment of MM... - Latest advances and current challenges in the treatment of multiple myelomaAnuj Mahindra
Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
Nat Rev Clin Oncol 9:135-43. 2012..A discussion of the challenges associated with these therapeutic approaches is also presented... - Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cellsSteffen Klippel
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
Br J Haematol 159:340-51. 2012..1S cells compared to vehicle-treated mice (P = 0·0046). These studies indicate that jasmonates represent a new, promising strategy to treat MM... - The treatment of multiple myeloma patients not eligible for asctPaul Richardson
Jerome Lipper Multiple Myeloma CenterDana Farber Cancer Institute and Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
Mediterr J Hematol Infect Dis 2:e2010009. 2010..Increasingly, novel agents are now being incorporated into therapy, based on the positive findings from clinical trials in this setting, and outcomes have improved accordingly... - Tailoring treatment for multiple myeloma patients with relapsed and refractory diseasePaul G Richardson
Harvard Medical School, Jerome Lipper Center for Multiple Myeloma, Dana Farber Cancer Institute, Boston, MA 02115, USA
Oncology (Williston Park) 24:22-9. 2010..Additional clinical challenges discussed in this article are renal dysfunction, extramedullary disease, and advanced bone disease. Finally, participation in clinical trials is especially encouraged in this patient population... - Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation studyIrene M Ghobrial
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Lancet Oncol 12:263-72. 2011..Our aim was to assess the response and safety of the combination of temsirolimus (an mTOR inhibitor) and bortezomib in patients with relapsed or refractory multiple myeloma... - Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune functionDouglas W McMillin
Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA 02215, USA
Blood 119:e131-8. 2012..This study provides a framework to identify novel immunomodulatory agents and to prioritize compounds for clinical development on the basis of their effect on antitumor immunity... - Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trialPaul G Richardson
Dana Farber Cancer Institute, 44 Binney St, Dana 1B02, Boston, MA 02115, USA
J Clin Oncol 29:4243-9. 2011..Clinical data suggest that perifosine in combination with dexamethasone has activity in relapsed or relapsed/refractory MM... - Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humansGüllü Topal Görgün
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
Blood 121:2975-87. 2013..Importantly, our studies suggest that inhibition of the tumor-promoting and immune-suppressive functions of MDSCs in MM may represent a promising novel immune-based therapeutic strategy... - New proteasome inhibitors in myelomaPanisinee Lawasut
Division of Hematologic Oncology, Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Mayer 228, Boston, MA 02215, USA
Curr Hematol Malig Rep 7:258-66. 2012..All of these second-generation PIs demonstrate encouraging anti-MM activity and appear to reduce the incidence of PN, with clinical trials ongoing... - Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implicationsJana Jakubikova
Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA
Blood 117:4409-19. 2011..Our studies demonstrate a novel mechanism of action for lenalidomide, namely targeting SP fraction, providing the framework for new therapeutic strategies targeting subpopulations of MM cells including presumptive stem cells... - Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implicationsDouglas W McMillin
Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute Department of Medicine, Harvard Medical School, Boston Novartis Institutes for BioMedical Research, Cambridge, MA 02115, USA
Br J Haematol 152:420-32. 2011..These observations provide insight into the biological relevance of multi-targeted CDK inhibition in MM... - Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomibPaul G Richardson
Division of Hematologic Malignancies, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
Blood 121:1961-7. 2013..This study is registered at http://www.clinicaltrials.gov as #NCT00833833... - Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and astheniaPaul G Richardson
Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
J Natl Compr Canc Netw 8:S4-S12. 2010..Regular screening and monitoring, combined with patient education and effective management strategies, can reduce the risk of these treatment-related complications, as well as their consequences... - Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomibConstantine S Mitsiades
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
Semin Hematol 46:166-75. 2009.... - Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myelomaConstantine S Mitsiades
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 29:1916-23. 2011..This review discusses these challenges, as well as potential strategies to address them, with the aim of making significant improvement in the clinical outcome of patients with MM... - Lenalidomide for the treatment of relapsed and refractory multiple myelomaNiels Wcj van de Donk
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Cancer Manag Res 4:253-68. 2012..This is accompanied by recommendations of how to manage and prevent adverse events associated with lenalidomide-based therapy... - Lenalidomide in multiple myeloma: an evidence-based review of its role in therapyPaul Richardson
Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancies, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Core Evid 4:215-45. 2010..Emerging evidence supports the ongoing investigation of lenalidomide in combination with low-dose dexamethasone, and in other combinations including bortezomib, for use both in relapsed, refractory, and newly diagnosed MM... - The spectrum of kidney involvement in lymphoma: a case report and review of the literatureLisa J Cohen
Nephrology Division, Brigham and Women s Hospital, Boston, MA, USA
Am J Kidney Dis 56:1191-6. 2010..We discuss a case of non-Hodgkin lymphoma and associated kidney failure from several distinct malignancy-related mechanisms and review the spectrum of lymphoma-related kidney involvement...